Klaria Pharma (KLAR) investor relations material

Executive summary

• Net sales for Q1 2026 were SEK 0.1 million, a sharp decline from SEK 9.0 million in Q1 2025, with a net loss after tax of SEK -8.7 million compared to SEK -1.6 million year-over-year.

• R&D expenses increased to SEK 4.9 million from SEK 3.4 million, reflecting continued investment in product development.

• Cash flow from operating activities was negative at SEK -0.1 million, and cash and cash equivalents at period end were SEK 0.3 million, down from SEK 1.5 million.

• Equity for the group was negative at SEK -20.6 million, a significant deterioration from SEK 1.7 million at the end of Q1 2025.

• Preparations for the launch of Sumatriptan Alginate Film in Europe continued, with large-scale manufacturing and regulatory dialogues ongoing.

Financial highlights

• Net sales: SEK 100 thousand (Q1 2025: SEK 8,985 thousand).

• Operating loss: SEK -7,207 thousand (Q1 2025: profit of SEK 2,987 thousand).

• Net loss after tax: SEK -8,655 thousand (Q1 2025: SEK -1,592 thousand).

• Cash flow from operating activities: SEK -82 thousand (Q1 2025: SEK 922 thousand).

• Cash and cash equivalents: SEK 260 thousand at period end (Q1 2025: SEK 1,520 thousand).

• Equity: SEK -20,610 thousand (Q1 2025: SEK 1,690 thousand).

Outlook and guidance

• The company expects significant revenue opportunities over the next twelve months from the launch of Sumatriptan Alginate Film, targeting a 10–30% share of the European Sumatriptan market.

• Ongoing business development efforts are focused on expanding into additional regions, including the US, Middle East, South America, and Asia-Pacific.

• Patent protection for Sumatriptan Alginate Film has been extended to 2045, supporting long-term market exclusivity.